Enanta Pharmaceuticals Inc
VKTX or ENTA: What to Expect from Revenue Growth in 2019
Wall Street analysts have projected Enanta Pharmaceuticals’ revenues to be $220.13 million, $193.28 million, and $166.89 million for fiscal 2019, fiscal 2020, and fiscal 2021, respectively.
What Are Analysts Recommending for VKTX and ENTA?
Of the nine analysts covering Viking Therapeutics, three have rated the company as a “strong buy,” and six have rated it as a “buy.”
Analysing NVR, DPZ, ENTA And QLYS Stocks
Growth stock analysis NVR NVR’s (NVR) net income has grown at a 3-year and 5-year average of 24% and 24.3% respectively. The company’s pre-tax margin grew from 9.9% in 2013 to 13.4% in 2017. The stock prices have beaten the residential construction industry between 2013 and 2017. The stock was beaten in 2013 and […]
Total Returns and Sector Exposure for Growth Indexes—Continued
The S&P 900 Growth and S&P 900 Pure Growth indexes have three-year annualized returns of 13% and 9.7%, respectively.
Total Returns and Sector Exposure for Growth Indexes
If we dig into the S&P 500 and the S&P Growth indexes, we can see that they have the highest exposure to information technology (or IT).
Analysts’ Ratings for Enanta Pharmaceuticals and Peers in April
Of the four analysts covering Enanta Pharmaceuticals, one analyst gave the stock a “buy” rating and three analysts gave it a “hold.”
Exploring Enanta Pharmaceuticals’ Product Pipeline
Enanta Pharmaceuticals initiated a Phase 2 clinical study of EDP-305 in PBC patients in December 2017.
A Look at Enanta Pharmaceuticals’ Financial Performance
In 1Q18, Enanta Pharmaceuticals (ENTA) generated total revenues of $38.1 million compared with $10.4 million in 1Q17.